Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab:
- PDF / 1,193,188 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 59 Downloads / 182 Views
ORIGINAL ARTICLE
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study Yohei Nose1,2 · Yoshinori Kagawa1 · Taishi Hata1 · Ryota Mori1,2 · Kenji Kawai1 · Atsushi Naito1,3 · Takuya Sakamoto1 · Kohei Murakami1 · Yoshiteru Katsura1 · Yoshiaki Ohmura1 · Toru Masuzawa1 · Atsushi Takeno1 · Yutaka Takeda1 · Takeshi Kato1,4 · Kohei Murata1 Received: 8 May 2020 / Accepted: 11 August 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients. Additionally, FTD/TPI plus bevacizumab (BEV) has demonstrated promising efficacy for mCRC patients who are refractory to standard chemotherapy. Chemotherapy-induced neutropenia (CIN) has been reported to be an indicator of efficacy for FTD/TPI. This study investigated whether CIN was an indicator of efficacy for FTD/TPI plus BEV. Methods We reviewed chemo-refractory mCRC patients who were treated with FTD/TPI alone (monotherapy) or FTD/TPI plus BEV (combination) at our institution and compared the safety and efficacy of the two. Progression-free survival (PFS) and OS were analyzed using Kaplan–Meier curves. We also investigated correlations between CIN and outcomes. Results In total, 56 patients received FTD/TPI, among whom 24 and 32 were treated with monotherapy and combination therapy, respectively. The median PFS was 1.8 and 4.7 months for the monotherapy and combination arms, respectively (hazard ratio [HR]: 0.28; 95% confidence interval [CI]: 0.15–0.51; P
Data Loading...
